A Randomized Phase II Study of Sequencing Abiraterone Acetate and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
This study is being offered to patients who have castrate-resistant (also known as
hormone-refractory) prostate cancer. The cancer has metastasized or spread outside the
prostate area to other parts of the body.
The purpose of this study is to evaluate the effects of sequencing hormonal therapies
(abiraterone acetate and enzalutamide) and to assess treatment efficacy of these two agents.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society